转移性葡萄膜黑色素瘤生存的分子决定因素:SF3B1突变的影响
该回顾性队列研究分析了220例原发性葡萄膜黑色素瘤患者的临床与分子数据,其中79例(36%)发生转移。研究发现3号染色体单体缺失和8q扩增与原发性UM的无复发生存期缩短相关,但不影响MUM的总生存期;SF3B1突变则与MUM显著更长的总生存期相关(31.7 vs 11.8个月,p=0.001),多因素分析证实其独立预后价值(HR=0.26,p=0.01)。
要点
- 3号染色体单体缺失和8q扩增可分层原发性UM的无复发生存期,但不预测MUM总生存期。
- SF3B1突变与MUM总生存期显著延长相关(31.7 vs 11.8个月,p=0.001)。
- SF3B1突变的预后价值独立于tebentafusp治疗。
核心结论
- 传统染色体标志物可分层原发性UM但无法预测MUM的总生存期。
- SF3B1突变是MUM的新型预后因素,提示 distinct 生物学表型并具潜在治疗意义。
研究设计与样本
- 回顾性分析前瞻性队列研究的临床与分子数据,纳入220例在Hospital de Bellvitge治疗的原发性UM患者,其中79例(36%)发生转移。
- 对原发肿瘤进行GNAQ、GNA11和SF3B1热点突变检测,并通过MLPA评估染色体3、8、1和6的体细胞拷贝数改变。
- 采用Kaplan-Meier和Cox比例风险模型评估遗传改变对无复发生存期和总生存期的影响。
主要发现
- 3号染色体单体缺失和8q扩增与原发性UM更短的无复发生存期相关(p<0.0001),但不影响MUM的总生存期(p=0.33)。
- SF3B1突变与MUM显著更长的总生存期相关(31.7 vs 11.8个月,p=0.001)。
- 多因素分析独立证实SF3B1突变的预后价值(HR=0.26,p=0.01),且不依赖于tebentafusp治疗。
临床怎么用
- 对原发性UM患者可检测3号染色体单体缺失和8q扩增以评估无复发生存风险。
- 对MUM患者可考虑检测SF3B1突变以获取预后信息。
- SF3B1突变状态可能有助于识别从特定治疗中获益的MUM亚群,但需进一步验证。
局限性
- 回顾性分析设计可能存在选择偏倚。
- 样本来自单一中心,结果外推需谨慎。
- SF3B1突变的预后及治疗相关性仍需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether key molecular alterations in primary uveal melanoma (UM), including mutations and somatic copy number alterations (SCNAs), serve as prognostic markers in metastatic UM (MUM). EXPERIMENTAL DESIGN: Retrospective analysis of a prospective cohort study of clinical and molecular data from UM and MUM patients. RESULTS: A total of 220 patients with primary UM treated at Hospital de Bellvitge, including 79 (36 %) who developed metastases, primarily in the liver. Genetic analyses of primary tumors included hotspot mutation testing for GNAQ, GNA11, and SF3B1, along with SCNA assessment (chromosomes 3, 8, 1, and 6) via Multiplex Ligation-dependent Probe Amplification (MLPA). Kaplan-Meier and Cox proportional hazards models assessed the impact of genetic alterations on relapse-free survival (RFS) and overall survival (OS). RESULTS: Monosomy 3 (M3) and chromosome 8q amplification (8A) were associated with shorter RFS (p < 0.0001) in primary UM but did not impact OS in MUM (p = 0.33). SF3B1 mutations (SF3B1m) conferred significantly longer OS in MUM (31.7 vs. 11.8 months, p = 0.001), independently confirmed in multivariate analysis (HR=0.26, p = 0.01), irrespective of tebentafusp treatment. CONCLUSIONS: Traditional chromosomal markers stratify primary UM but fail to predict OS in MUM. SF3B1m emerges as a novel prognostic factor, indicating a distinct biological phenotype with potential therapeutic implications. Further studies are warranted to validate its prognostic and therapeutic relevance in MUM.
引用
- Del Carpio LP, Varela M, Portu M, et al. Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations. Eur J Cancer. 2025. PMID: 40628177. doi:10.1016/j.ejca.2025.115591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。